Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review1006 has been discontinued.
View all Adrenergic α<sub>1</sub> Receptors products.BMY 7378 dihydrochloride is a 5-HT1A partial agonist and high affinity α1D adrenoceptor antagonist (Ki values are 2, 800 and 600 nM at cloned rat α1D, rat α1A and hamster α1B receptors, respectively).
M. Wt | 458.42 |
Formula | C22H31N3O3.2HCl |
Storage | Store at RT |
CAS Number | 21102-95-4 |
PubChem ID | 24744861 |
InChI Key | HZRPUQURUAXOHB-UHFFFAOYSA-N |
Smiles | O=C1CC4(CCCC4)CC(N1CCN(CC3)CCN3C2=CC=CC=C2OC)=O.Cl.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Gruel and Glaser (1992) The putative 5-HT1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro. Eur.J.Pharmacol. 211 211 PMID: 1535319
Piascik et al (1995) The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J.Pharmacol.Exp.Ther. 275 1583 PMID: 8531132
Sharp et al (1990) Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378. Eur.J.Pharmacol. 176 331 PMID: 1970304
Yang and Endoh (1997) Pharmacological evidence for β1D-adrenoceptors in the rabbit ventricular myocardium: analysis with BMY 7378. Br.J.Pharmacol 122 1541 PMID: 9422797
Keywords: BMY 7378 dihydrochloride, BMY 7378 dihydrochloride supplier, Selective, α1D-adrenoceptor, alpha1D-adrenoceptor, a1d-adrenoceptor, α1d-adrenergic, alpha1d-adrenergic, a1d-adrenergic, antagonist, 5-HT1A, partial, agonists, Receptors, Serotonin, BMY7378, dihydrochloride, Adrenergic, Alpha-1, 1006, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for BMY 7378 dihydrochloride include:
Gadgaard & Jensen (2020) Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay. Biochem Pharmacolg 175 PMID: 32088264
Kahn et al (2016) The anti-hypertensive drug pra. inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway. EMBO Mol Med 8 511 PMID: 27138566
Song et al (2010) Multiple alpha1-adrenergic receptor subtypes support synergistic stimulation of vasopressin and oxyt. release by ATP and phenylephrine. Am J Physiol Regul Integr Comp Physiol 299 R1529 PMID: 20881098
Lee et al (2010) Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One 5 e14123 PMID: 21152063
Atkins et al (2010) Circadian integration of glutamatergic signals by little SAAS in novel suprachiasmatic circuits. PLoS One 5 e12612 PMID: 20830308
Grisanti et al (2011) α1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages. J Pharmacol Exp Ther 338 648 PMID: 21571945
There are currently no reviews for this product. Be the first to review BMY 7378 dihydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.